Johnson & Johnson (JNJ)vsLive Ventures Inc (LIVE)
JNJ
Johnson & Johnson
$221.32
-0.53%
HEALTHCARE · Cap: $535.63B
LIVE
Live Ventures Inc
$13.25
+0.61%
CONSUMER CYCLICAL · Cap: $37.66M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 21702% more annual revenue ($96.36B vs $441.98M). JNJ leads profitability with a 21.8% profit margin vs 5.0%. LIVE trades at a lower P/E of 2.6x. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LIVE
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.5%
Fair Value
$160.72
Current Price
$221.32
$60.60 premium
Margin of Safety
+89.0%
Fair Value
$177.00
Current Price
$13.25
$163.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 26 in profit
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
5.0% margin — thin
Operating margin of 3.2%
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : LIVE
The strongest argument for LIVE centers on P/E Ratio, Price/Book, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : LIVE
The primary concerns for LIVE are Market Cap, Profit Margin, Operating Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LIVE is a value play — different risk/reward profiles.
LIVE carries more volatility with a beta of 1.06 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 44/100), backed by strong 21.8% margins. LIVE offers better value entry with a 89.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Live Ventures Inc
CONSUMER CYCLICAL · HOME IMPROVEMENT RETAIL · USA
Live Ventures Incorporated is engaged in flooring manufacturing, steel fabrication and retail businesses in the United States. The company is headquartered in Las Vegas, Nevada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?